In September 2011 Dr. Harold Varmus, Director of the US National Cancer Institute (NCI) appointed Dr. Trimble Director of the NCI’s new Center for Global Health. Between 1991 and 2011, Dr. Trimble was Head, Gynecologic Cancer Therapeutics and Quality of Cancer Care Therapeutics, Clinical Investigation Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, at the NCI. His duties were as scientific liaison with the Gynecologic Oncology Group and the American College of Surgeons Oncology Group, as well as oversight of issues involving the elderly, minorities, women’s health, international collaboration, cost, cancer health disparities, health-related quality of life and patient-reported outcomes in NCI-sponsored treatment trials. For his work at NCI he has received two Public Health Service Commendation Medals, 6 NIH Merit Awards, and the NCI Director’s Gold Star Award.
Following graduation from Harvard College and the Johns Hopkins University School of Medicine, Dr. Trimble trained in obstetrics and gynecology at the Vanderbilt University Medical Center. He earned a master’s degree in public health from the Johns Hopkins School of Hygiene and Public Health, and then completed a fellowship in gynecologic oncology at Memorial Sloan-Kettering Cancer Center. He is board-certified in obstetrics and gynecology, as well as in gynecologic oncology, by the American Board of Obstetrics and Gynecology.
Medical School: Harvard College, Johns Hopkins University School
Residency: Vanderbilt University
Master’s degree: Johns Hopkins School of Hygiene and Public Health
Fellowship: Memorial Sloan-Kettering Cancer Center
Board Certified: Obstetrics and Gynecology, Gynecologic Oncology
Mary Eiken has been a senior executive for over 20 years with experience in the field of
association management. For 12 years, she was CEO the Society of Gynecologic Oncology
(SGO) and their Foundation, The Foundation for Gynecologic Oncology. During her tenure she
moved the organizations from a management firm to a self-managed environment. She has
implemented strong governance, policy, procedures and three strategic plans over the course of
the twelve years. Mary has enhanced the organizations presence in Washington DC through
strategic partnerships and expanding the advocacy programs to include Capitol Hill visits and
collaborating with patient survivor organizations.
In April 2016 Mary became the first CEO of the International Gynecologic Oncology Society
(IGCS). Her expertise in governance, policy, strategic planning, relationship building and
volunteer engagement will bring about positive change to the Society.
Mary received her undergraduate degree in nursing from the U of Iowa and a Master degree from
DePaul University. She is a past board member of the Association Forum of Chicago land where
she has volunteered in many different capacities with the Forum. She is also active in the
American Association for Medical Society Executive (AAMSE) and Be Bright Pink and several
other advocacy based organizations.
Undergraduate degree: University of Iowa
Master`s degree: DePaul University
Dr. Wendel Naumann is a Professor in the Department of Ob/Gyn at Carolinas Medical Center which is the Charlotte Campus of University of North Carolina School of Medicine.
He attended medical school, residency in Ob/Gyn, and fellowship in Gynecologic Oncology at the University of Alabama School of Medicine in Birmingham, Alabama. He is currently the Director of Minimally Invasive Surgery in Gynecologic Oncology at the Levine Cancer Institute in Charlotte, North Carolina.
He has severed on the Board of directors for the Society of Gynecologic Oncology (SGO) and is the Former Chair of the SGO Education Committee. He has an interest in complex minimally invasive surgery and has been the primary investigator in several clinical trials in ovarian and uterine cancer.
Medical School: The University of the South Sewanee, Tennessee
Residency: University of Alabama
Fellowship: University of Alabama
Board Certified: Obstetrics and Gynecology, Gynecologic oncology
Jubilee Brown, MD is a board certified gynecologic oncologist who was on faculty at M.D. Anderson Cancer Center for over 15 years prior to joining Levine Cancer Institute. She specializes in caring for women with uterine, ovarian, cervical, vulvar, vaginal, and rare gynecologic cancers, and women at high risk for these conditions.
Dr. Brown is an expert in minimally invasive (laparoscopic and robotic) surgery, and has trained physicians worldwide in these techniques. She has authored more than 75 articles, 21 chapters, and she has edited one textbook. She has lectured on 5 continents and served on the Board of Trustees of the AAGL and FMIGS.
Dr. Brown is considered a worldwide authority on rare gynecologic malignancies, and has been the principal investigator on two GOG cooperative group trials and has co-authored 3 of the GCIG treatment guidelines for rare gynecologic cancers. Dr. Brown is currently welcoming new patients at the Levine Cancer Institute and is working to establish one of the nation's premier hereditary cancer centers.
Medical School: University of Cincinnati
Residency: University of Maryland
Fellowship: The University of Texas M.D. Anderson Cancer Center
Dr. Tom Randall is a gynecologic oncologist at the Massachusetts General Hospital and a senior advisor for gynecologic cancers for the National Cancer Institute’s Center for Global Health. His interests in global oncology are in optimizing and scaling up cervical cancer screening and in capacity building for treatment of gynecologic cancers in resource limited settings. He also has an interest in building capacity for minimally invasive surgery in low resource settings. He currently is working on projects in Rwanda and in Uganda.
Dr. Randall works as a volunteer for the Dana Farber Cancer Institute Center for Global Cancer Medicine and he serves on the Advisory Board of Global Oncology.
Board Certified: Gynecologic Oncology
Anna Plotkin is Assistant Professor at the Department of Laboratory Medicine and Pathobiology at the University of Toronto and a clinical pathologist practicing at Trillium Health Partners, Mississauga, Ontario,Canada, the largest academic community hospital in Canada, servicing a population base of over 1.5 million.
She obtained residency in anatomical pathology at the University of Toronto, followed by a fellowship in gynecologic and breast pathology. She is also cross appointed to the Department of Obstetrics and Gynecology at Trillium Health Partners and is a gynecologic resource pathologist for the Division of Gynecologic Oncology and area served.
Anna's primary interest is in education on all levels: undergraduate, graduate and postgraduate as well as educating clinicians about the field of diagnostic oncology. She has won several awards for her continuing contribution to teaching from both the University of Toronto and Trillium Health Partners. Anna serves on different clinical committees and is an active member of Cancer Care Ontario's Colposcopy Clinical Advisory Group and the Gynecologic Cancer Advisory Committee. She is also Vice-President of the Ontario Association of Pathologists.
Residency in anatomical pathology: University of Toronto
Fellowship in gynecologic and breast pathology: University of Toronto
He founded, in the early 2000’s, IOSI – Oncology Institute of Southern Switzerland, in Bellinzona. In 2006 he joined the Swiss Genolier Medical Network, where since then he has been chairing the Radio-Oncology Department. In 1993 he received the Yalow-Berson Award, in St Louis, USA, for his laboratory work on interferons and interleukins. In a recent past he has been instrumental in introducing the concept of post-operative chemo-radiation in head & neck cancers and leading a seminal EORTC study, the results of which were published in the New England Journal of Medicine. From 2000 to 2006 Jacques Bernier was Chairman of the Head and Neck Group of the EORTC. He currently serves as an Editorial Board member of various international peer-reviewed journals, including “Journal of Clinical Oncology”. He was an Associate Editor of “Annals of Oncology” (2010-2013) and of “Oral Oncology” (2011-2016), he is also Editor of a Textbook entitled « Head and Neck Cancer: Multimodality Management». In 2010, Jacques Bernier was awarded the “Claudius Regaud Medal” by the European Society of Therapeutic Radiology and Oncology - ESTRO. A Course Director at the European School of Oncology since 1990, Jacques Bernier is also the Chairman of the International Conference on Translational Research in Radio-Oncology - ICTR. He is President of the «Foundation for the Advancement of Radiation Oncology – FARO», in Geneva.
In 2009, he pioneered the use of intra-operative radiotherapy for breast cancer, in Switzerland (ELIOT). In 2014, he created the Genolier Swiss Oncology Network (GSON), and in 2016, he received the accreditation from the Swiss Cancer Network as member of the core team of the GSON. He is currently member of the Board of the Genolier Breast Unit, accredited by the Swiss League against Cancer and the Swiss Society of Senology. In July 2016, he was elected President of the Euro-Asian Society of Mastology – EURAMA, in Milan, Italy.
Medical School: University of Liege, Belgium
MD,PD: MD Anderson Cancer Center, Houston, and the Curie Institute, Paris
Principal subjects: Radiotherapy of Head and Neck cancers, breast cancer, lymphomas, prostate carcinomas. Translational Research in radio-oncology
Since the October 2015 Stefano Zurrida is Professor of General Surgery at the Milan University School of Medicine, Milan, Italy. From April 2010 to October 2015, Professor Zurrida has been Director of the Integrated Breast Diagnosis and Surgery Unit at the European Institute of Oncology, Milan. From January 2008 to 2013 he was a member of the Board of Management of the Superior Institute of Health, Rome, being appointed by the Italian Minister of Health. Professor Zurrida is also concerned with the planning and building of new technologically advanced cancer centres. This started 1991 when he was involved in consultations on the building of the European Institute of Oncology, Milan, and the Sant’Elena In 2010 he became involved in planning the Italian Hospital in Istanbul.
Professor Zurrida has authored more than 400 scientific publications, most of which have appeared in peer reviewed journals of international stature cited in Index Medicus. He is co-author of the highly successful book “Breast Cancer: A Guide for Fellows”. He recently published the second edition of his book “Healthy Eating: Fact and Fiction” to coincide with the start of EXPO 2015 in Milan.
In July 2010 he was awarded the Umberto Veronesi Prize for excellence in medical education given during the Inter-American Breast Cancer Congress, Cancun, Mexico. He is a member of numerous scientific societies.
1981 - 1982 - Internship at the Hematology Department of Medical Clinic of Università degli Studi di Milano - Chief of Department Prof. E. Polli.
July 1987- July 1989 - Staff member as Research Assistant at Wayne State University (Detroit – USA), Head and Neck Service Tumor Cell Lab. under supervision of J.F. Ensley and M. Alsarraf
November 1989 – November 1990 - Researcher at Institute Gustave Roussy (Paris) with a Grant from European Community on “Biological and histological parameters as prognostic factors and predictors of response to induction chemotherapy for operable T2 and T3 squamous cell carcinoma of oropharynx”
June 1990- 1994 - Assistant Attending Physician at the Medical Oncology Division B of Istituto Nazionale per lo Studio e la Cura dei Tumori, – Milan, Italy (Chief of Division E. Bajetta, MD)
April 1994-November 2000 - Deputy Director of Medical Oncology Division at the European Institute of Oncology- Milan, Italy.
March 2012 – March 2017 - Director of Medical Oncology Department at Fondazione IRCCS Istituto Nazionale dei Tumori, - Milan, Italy
2015 - Ongoing - Full Professor of Medical Oncology appointed to Department of Clinical and Community Science, Università degli Studi di Milano, Italy
He is leading researchers in new drugs development (Phase I and early Phase II studies) and conducting as Principal Investigator several international studies in development of new drugs. Co-Editor of START Project (State of the Art Oncology in Europe ) He is Tutor for Italian and foreign students in Medical Oncology. Dr de Braud is the author or coauthor of over 340 publications in medical oncology and over 30 chapters of books
Medical University: Università degli Studi – Milan, Italy
Specialization: European certified oncologist-chemotherapist
Specialty: Clinical Oncology, University of Milan, Italy/p>
Since the 1th of August 2017 Prof. Giancarlo Pruneri is Director of the Division of Pathology, Fondazione IRCCS National Cancer Institute, Milan.
Since 2015 to date: Associate Professor in Pathology, University of Milan, School of Medicine, Milan, Italy. Senior Vice-Director, Division of Pathology, European Institute of Oncology, Milan, Italy
From 2015-2017: Director Biobank for Translational Medicine (B4MED), European Institute of Oncology, Milan, Italy.
Education, license and certifications:
1992: MD degree, University of Milan
1996: Specialization in Pathology, University of MilanProf. Pruneri has been recipient of a number of different national and international grants including Grant “The role of Polycomb group proteins in oncogenesys and cell reprogramming. Applications in cancer therapy and regenerative medicine – 2009”), Transcan (“CD3 and CD20 lymphocytes infiltration predict chemosensitivity in patients with triple negative breast cancer (UGI1) – 2013”), Avon (Clinical and molecular identification and characterization of population of women with breast or ovarian cancer at risk of concomitant or concomitant ovarian or breast cancer.-2016).
Prof. Pruneri joined the International Breast Cancer Study Group, led by Prof. Goldhirsch, where he was appointed as Chair of the Translational Research Working Group, that is dedicated to initiate, foster and develop translational research in tissues from IBCSG clinical trial, as the BIG1-98 and, more recently, SOFT and TEXT. He took an active role in designing international, phase III randomized clinical trials, as the ALTTO trial comparing Herceptin and Lapatinib in Her-2 positive breast cancer patients.
In 2004, Andrea Spano completed a residency in plastic surgery. After graduation from 2004 to 2005 he worked in the department of plastic and reconstructive surgery under the direction of Stan Monstry and Phillip Blondil, University Hospital Genta, Belgium.
From 2006 to the present time he is the director of the oncoplastic branch of the National Cancer Institute ", Milan, Italy.
Andrea Spano is a professor at the University under the program of teaching plastic surgery and has repeatedly been a scientific and surgical supervisor for many residents and fellows. Constantly participates and organizes international conferences, has many published articles in medical journals.
Andrea Spano is involved in many international master classes, as a high-level surgeon. He is a principal investigator in many clinical studies: Strattice, PHI-5, Tissuecoll and many others.
Medical University: Università degli studi di Brixiae
Fellowship: Plastic Surgery
Master`s Degree: Master in Biotechnologies and Tisuue Engeneering
Training: Plastic Surgery Universitary Training Program (University of Milan)
Specialization: Plastic Reconstructive Surgery and Microsurgery
Dr. Gultekin is a Gynae Oncologist, an associated Professor and lately a government official as cancer director in MoH, who is actively involved in several leading cancer organizations, such as being vice president of the European Society of Gynaecological Oncology (ESGO) and council member of the International Agency for Research on Cancer (IARC), European Commission Expert Group on Cancer Control and World Health Organization (WHO) and President of Blacksea Coalition for Cervical and Breast Cancer.
He has been the leading founder of HPV DNA Screening, Mobile Trucks and Central Mammography Report Unit, cancer registry systems in Turkey and so called Pallia-Turk project within Turkish Ministry of Health. He is a member of the editorial board of several international cancer journals and prominent oncology textbooks, including ESGO's Textbook of Gynaecological Oncology and author of over 80 articles in SCI indexed publications.
Medical University: Hacettepe University
Obstetrics & Gynecology (Ob/Gyn) Expert Hacettepe University
School of Medicine:Hacettepe University
Turkish ParliamentCancer Research Commission Expert